drugset / Trial / NCT06889610
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.
Timeline
- Start
- 2026-03-30
- Primary completion
- 2027-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | — |
| Subject | Eribulin | Small molecule | — | — |
| Subject | Fruquintinib | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Pucotenlimab | Monoclonal antibody | — | — |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | — |
| Subject | Toripalimab | Monoclonal antibody | — | — |
| Subject | UTD1 | Unknown | — | — |